Shares of Perrigo Co. gained 2.1% in trading on Monday after the company said a Food and Drug Administration advisory committee meeting has been scheduled to review the application for an over-the-counter birth control. The meeting is set for Nov. 18. The medication, a daily oral contraceptive, is called Opill. If approved, it would be the first OTC birth control pill in the U.S. Perrigo's stock is up 2.6% this year, while the broader S&P 500 has declined 14.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
